Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
— Claus Andersson, PhD, joins Rewind´s Board of Directors
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics´ Board of Directors. Financial details of the transaction were not disclosed.